BioSpace News Archive

-- Proceeds support advancement of Precision Oncology 2.0 drug-hunting engine and first wave of therapeutic candidates -- -- Company management to present at 39 th Annual J.P. Morgan Healthcare Conference --

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met its primary and both secondary endpoints at nine months in patients with hATTR amyloidosis with polyneuropathy.

Fiscal 2021 Second Quarter Highlights Net sales of $72.8 million increased 4.0% compared to the prior-year quarter Gross margin declined 410 basis points year over year to 55.2% GAAP loss per share of $0.11 and adjusted earnings per share of $0.01 Cash and cash equivalents on November 30, 2020 were $58.0 million, compared to $47.9 million on August 31, 2020 The Company reaffirms its guidance of fiscal year 2021

-- Partnership combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development -- -- ArsenalBio employs a suite of proprietary technologies to encode synthetic biological instructions to overcome solid tumors’ complex defense systems --

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today the initiation of an expanded access program (EAP) for loncastuximab tesirine

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021 Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel discussion on precision medicine on Wednesday, January 13, 2021 at 9:00 a.m. PT / 12:00 p.m. ET. T

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a company overview and pipeline update at the 39th Annual J.P. Morgan Conference, being held virtually, on Thursday, January 14, 2021 at 2:50 p.m. ET. A live webcast of the presentat

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 202

BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD).

Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today its Chief Executive Officer, President and Member of its Board of Directors Dr. Neil J. Campbell